Summary
Aromatase inhibitors are important agents used for the adjuvant treatment of early hormone receptor-positive breast cancer in postmenopausal women. Studies in early stage breast cancer are ongoing to determine if the cellular proliferation biomarker Ki67 predicts patient response to therapy. Genetic analysis of biopsy specimens may help identify resistance mechanisms.
- hormone receptor-positive
- postmenopausal women
- breast cancer
- clinical research
- biomarker analysis
- anastrozole
- tamoxifen
- Arimidex, Tamoxifen Alone or in Combination
- ATAC
- NCT00894030
- Immediate Preoperative “Arimidex” (anastrozole), Tamoxifen, or Arimidex Combined with Tamoxifen
- IMPACT
- Trial of Perioperative Endocrine Therapy – Individualising Care
- POETIC
- NCT02338310
- © 2014 SAGE Publications
Tools
Table of contents
Cited By...
- No citing articles found.